0

Neutropenia - A Pipeline Analysis Report

  • Published: Jun 2018
  • Pages: 116
  • SKU: IRTNTR22302
Technavio

The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted
  • 2500.00
  • USD

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for neutropenia including molecules at phase I, phase II, and phase III development stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, by mechanism of action, therapeutic modality, and target.

Overview of the drug development pipeline for neutropenia  

Neutropenia occurs owing to the low count of white blood cells in the body, termed as neutrophils. Leukemia is the most common type of cancer occurring in adults and children. Individuals with neutropenia are susceptible to contracting serious infections, that result in occurring of various cancers in the body. Patients experience symptoms such as ulcers, abscesses, rashes, pneumonia, and fever. Medical practitioners have identified that neutropenia occurs due to decreased bone marrow production and increased destruction of neutrophils in the peripheral blood. With the increasing instances of neutropenia in children and adults, Technavio's market research analysts have reported increasing drug development for therapeutics to treat neutropenia in the forthcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the pre-clinical and phase II drug development stage. Our market research analysts have also identified that almost same amount of drug molecules are under the phase I and discovery drug development stage. The pipeline landscape in the pipeline analysis report also mentions the percentage of drug development molecules that are in the phase II/III and phase III stage. 

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of neutropenia. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

  • PROLONG PHARMACEUTICALS
  • SPECTRUM PHARMACEUTICALS  
  • SYROS PHARMACEUTICALS  

Therapeutic assessment of the drug development pipeline for neutropenia by route of administration

  • Subcutaneous
  • Oral
  • Intravenous

In the subcutaneous route of administration (ROA), the drug substances are administered directly into the layer of the skin below the dermis and the epidermis. It has been observed that the majority of total therapeutics for neutropenia are being developed for subcutaneous administration.  

Therapeutic assessment of the drug development pipeline for neutropenia by therapies employed

  • Monotherapy
  • Combination therapy

According to this pipeline analysis report, molecules are developed in the monotherapy method of therapeutics. In this therapy employed, a single drug is administered to treat a particular disorder.

Technavio also offers customization on reports based on specific client requirement.

Read More Read Less

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

PART 05: MAJOR REGULATORY AUTHORITIES

  • US
  • Europe
  • China

PART 06: PIPELINE LANDSCAPE

PART 07: COMPARATIVE ANALYSIS

  • Discovery stage molecules
  • Pre-clinical stage molecules
  • Inactive and discontinued molecules

PART 08: INDICATION ANALYSIS

PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)

PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)

PART 11: THERAPEUTIC ASSESSMENT BY TARGET

PART 12: KEY COMPANIES

  • Active companies: Category and parameters

PART 13: APPENDIX

  • List of abbreviations

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

TechnavioINFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases
Technavio

TechnavioDATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts
Technavio

TechnavioREPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your FREE sample now!
Safe and Secure SSL Encrypted
Technavio

Single User:

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer $1000 worth of FREE customization at the time of purchase
Technavio
Enquire Before Buying
  1. Home
  2. Health Care
  3. Published Report
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>